Project Grant R43AI197297
Award Date 8/12/26
Completion Date 7/31/28
Dollars Obligated $295K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Monmouth Junction, South Brunswick Township, NJ 08852, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Trustees of Tufts College (doing business as Tufts University School of Medicine) $151,040 on January 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify and characterize the unique cell division machinery of Clostridioides difficile, a major nosocomial pathogen. The research addresses a critical gap in understanding bacterial cell division. Unlike model organisms studied over decades,...
- The National Institute of Allergy and Infectious Diseases awarded $182,424 to Trustees of Tufts College (doing business as Tufts University School of Medicine) on October 24, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on the effect of epithelium association and toxin gene expression on Clostridioides difficile disease severity. The research addresses the mechanisms driving disease severity in C. difficile infection (CDI), the most common...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services National Institutes of Health, awarded $437,541 to Virginia Polytechnic Institute & State University on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop antisense therapeutics targeting Clostridioides difficile infection. The research focuses on designing antisense oligomers, including peptide nucleic acids, to suppress...
- The National Institute of Allergy and Infectious Diseases awarded Datanova Scientific LLC $306,969 on July 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop TRACE-CDI, a digital platform for automated root cause analysis of hospital-acquired Clostridioides difficile infections. The project delivers a scalable, technology-driven system that integrates electronic health records and hospital data to streamline root cause analysis and improve infection...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $599,327 to Microbiotix, Inc. on September 22, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel benzyl-piperidine antifungal agents targeting intractable mucormycosis infections caused by drug-resistant Mucorales fungi. The project focuses on chemical optimization of a benzyl-piperidine series to improve drug-like properties and...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, San Francisco $246,000 on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a hidden Markov modeling framework that characterizes the full clinical progression of Clostridioides difficile infection using patient-level electronic health data. The project addresses gaps in current analytic approaches that treat CDI as a single symptomatic...
- The National Institute of Allergy and Infectious Diseases awarded Beth Israel Deaconess Medical Center, Inc. $987,730 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop next-generation spectinomycin analogs that evade adenylase-based resistance mechanisms and demonstrate enhanced potency against multidrug-resistant gram-negative pathogens including carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii. The...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the University of Iowa $684,797 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the genetic requirements for lipoteichoic acid synthesis in Clostridioides difficile. The research addresses antibiotic resistance in C. difficile, the leading cause of hospital-acquired infectious diarrhea. Current treatment options...
- The National Institute of Allergy and Infectious Diseases awarded Trustees of Tufts College (doing business as Tufts University School of Medicine) $227,640 on September 30, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the molecular mechanisms regulating amidase activity during Clostridioides difficile spore development. The research uses genetic, biochemical, and structural approaches to determine how the CWLD amidase enzyme is activated,...
- The National Institute of Allergy and Infectious Diseases awarded Cmtx Biotech Inc. $296,470 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel liposomal formulation of rebamipide as an adjunctive host-directed treatment for Staphylococcus aureus bacteremia. Cmtx Biotech will conduct Phase I Small Business Technology Transfer research to address the high morbidity and mortality associated with S. aureus bloodstream infection, which...